Open an account

Medifast

MED · NYSE

$12.06+$0.03 (+0.25%)TodayMarket closed ·
Prev close $12.03

About MED

Medifast, Inc. is a health and wellness company, which engages in the provision of habit-based and coach-guided lifestyle solutions called OPTAVIA. The company is headquartered in Baltimore, Maryland and currently employs 380 full-time employees. The firm is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. The company sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.

Employees
380
Headquarters
Baltimore, Maryland
Listed
Dec 30, 1993
Sector
Consumer Staples
Industry
Personal Care Products
Website
medifastinc.com

MED key statistics

Market cap
134.84M
Price-earnings ratio
0.00
Dividend yield
0.13%
Average volume
110.56K
Volume
125.11K
Open price
$12.10
High today
$12.18
Low today
$11.94
52 Week high
$13.58
52 Week low
$9.22

Medifast (MED) at a glance

As of Oct 20, 2026, Medifast (MED) shares are priced at $12.06, giving the company a market cap of 134.84M, a price-to-earnings ratio of 0.00 and a dividend yield of 0.13%.

Today the stock has traded between $11.94 and $12.18. The current price is 1.0% above the day's low and 0.9% below its high.

Volume so far is 125.11K shares, in line with the average of 110.56K shares a day.

Over the past year Medifast has ranged from $9.22 to $13.58, and now sits 65% of the way up that range.

Medifast met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.28 per share against an estimate of -$0.6565.

The average analyst price target is $12.24, 1.5% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 2 analystsAvg $12.24
Low
$12.12
Now
$12.06
High
$12.60

MED earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 116.2% on average.

  1. Q3 FY24: reported $0.35 per share against an estimate of -$0.2798
  2. Q4 FY24: reported $0.10 per share against an estimate of -$0.1616
  3. Q1 FY25: reported -$0.11 per share against an estimate of -$0.2727
  4. Q2 FY25: reported $0.22 per share against an estimate of -$0.2222
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.3939
  6. Q4 FY25: reported -$1.65 per share against an estimate of -$0.8282
  7. Q1 FY26: reported -$0.19 per share against an estimate of -$0.5252
  8. Q2 FY26: reported -$0.28 per share against an estimate of -$0.6565

MED news

  • Press releaseBusiness Wire

    Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2026

  • Press releasePRNewswire

    Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update

  • Press releaseBusiness Wire

    Medifast® Announces the Launch of the Medifast Metabolic Health Institute™

  • 11 Consumer Staples Stocks Moving In Monday's After-Market Session

  • Press releaseBusiness Wire

    Medifast Announces Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026

  • Press releaseBusiness Wire

    Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System

  • Press releaseBusiness Wire

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

Similar companies

Companies in the same industry as Medifast

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.